BioWorld

April 14, 2008

PDL to Spin Off Biotech Assets into New Firm by End of Year

Nearly a month after taking steps to streamline the company, PDL BioPharma Inc. said it plans to spin off its biotechnology assets into a separate publicly traded firm. (BioWorld Today) Read More

Lung Cancer Phase III Trial Garners Antisoma $25M

Lower-Than-Expected Avastin Sales Mar Genentech's lst Quarter

NewCo News: Molecular LogiX Plans to Use (Dominant) Negativity for Good

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...